These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 18385765)

  • 1. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor targeting of adeno-associated virus vectors.
    Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
    Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
    Jooss K; Chirmule N
    Gene Ther; 2003 Jun; 10(11):955-63. PubMed ID: 12756416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.
    Sarukhan A; Camugli S; Gjata B; von Boehmer H; Danos O; Jooss K
    J Virol; 2001 Jan; 75(1):269-77. PubMed ID: 11119597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.
    Zhang YC; Powers M; Wasserfall C; Brusko T; Song S; Flotte T; Snyder RO; Potter M; Scott-Jorgensen M; Campbell-Thompson M; Crawford JM; Nick HS; Agarwal A; Ellis TM; Atkinson MA
    Gene Ther; 2004 Feb; 11(3):233-40. PubMed ID: 14737082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
    Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
    Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.
    Maersch S; Huber A; Büning H; Hallek M; Perabo L
    Virology; 2010 Feb; 397(1):167-75. PubMed ID: 19926109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
    Wu Z; Asokan A; Samulski RJ
    Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy progress and prospects--vectorology: design and production of expression cassettes in AAV vectors.
    Le Bec C; Douar AM
    Gene Ther; 2006 May; 13(10):805-13. PubMed ID: 16453010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
    Bessis N; GarciaCozar FJ; Boissier MC
    Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
    Couto LB
    Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in adeno-associated virus vector technology.
    Büning H; Perabo L; Coutelle O; Quadt-Humme S; Hallek M
    J Gene Med; 2008 Jul; 10(7):717-33. PubMed ID: 18452237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios.
    Aucoin MG; Perrier M; Kamen AA
    Biotechnol Bioeng; 2006 Dec; 95(6):1081-92. PubMed ID: 16952153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
    Rivière C; Danos O; Douar AM
    Gene Ther; 2006 Sep; 13(17):1300-8. PubMed ID: 16688207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing and characterizing AAV-based vectors for use in clinical studies.
    Wright JF
    Gene Ther; 2008 Jun; 15(11):840-8. PubMed ID: 18418418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.
    Davidoff AM; Gray JT; Ng CY; Zhang Y; Zhou J; Spence Y; Bakar Y; Nathwani AC
    Mol Ther; 2005 Jun; 11(6):875-88. PubMed ID: 15922958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring the AAV vector capsid for gene therapy.
    Vandenberghe LH; Wilson JM; Gao G
    Gene Ther; 2009 Mar; 16(3):311-9. PubMed ID: 19052631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and characterization of adeno-associated viral vectors.
    Grieger JC; Choi VW; Samulski RJ
    Nat Protoc; 2006; 1(3):1412-28. PubMed ID: 17406430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Innate immune mechanisms against recombinant adeno-associated virus vectors--a review].
    Diao Y; Xu R
    Wei Sheng Wu Xue Bao; 2012 May; 52(5):550-7. PubMed ID: 22803339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.